CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DEMECLOCYC SPECIFIC		*USP43–NF38*	1248	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LINE HYDROCHLORIDE	TESTS/*Loss on Drying*							Change Dry the *Sample* at 60° for 3 h. to: Dry the *Sample* in a capillary-stoppered bottle in vacuum at 60° for 3 h.
WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP43–NF38*	5552	24-Apr-2020	1-May-2020	*NA*	*NA*	In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis*: Add ascorbic acid (C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_6H_8O_6$),

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EPINEPHRINE	ADDITIONAL REQUIREMENTS	*USP43–NF38*	Online	24-Apr-2020	1-May-2020	*NA*	*NA*	This erratum applies to the USP-NF ONLINE platform only. In *USP Reference Standards* <*11*>: Add USP Racepinephrine Hydrochloride RS
SODIUM METABISULFITE	IMPURITIES/*Limit of Chloride*	*USP43–NF38*	6020	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change (see *Nephelometry, Turbidimetry, and Visual Comparison* <855>). to: (see *Visual Comparison* <630>).
MEXILETINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP43–NF38*	2943	24-Apr-2020	1-May-2020	*NA*	*NA*	Change [5370-01-04]. to: [5370-01-4].
NEAR-INFRARED SP	4. VALIDATION AND	*USP43–NF38*	7161	24-Apr-2020	1-May-2020	*NA*	*NA*	In *4.1 Validation/4.1.1*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ECTROSCOPY VERIFICATION								*Accuracy/Validation criteria*/*Criteria 1*: Change Suitable agreement between SEP to: Suitable agreement between the standard error of prediction (SEP)
PROPRANOLOL HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	3746	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability*/*Suitability requirements*/*Relative standard deviation*: Change NMT 5.0, to: NMT 5.0%,
RALTEGRAVIR CHEWABLE TABLETS	ASSAY/*Procedure*	*USP43–NF38*	3835	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
VITAMIN E	ASSAY/*Alpha Tocopheryl Acid Succinate*	*USP43–NF38*	4637	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Sample solution*: Change tocoopheryl to: tocopheryl
REPOSITORY CORTICOTROPIN INJECTIONS	ADDITIONAL REQUIREMENTS	*USP43–NF38*	1174	24-Apr-2020	1-May-2020	*NA*	*NA*	In *USP Reference Standards* <*11*>: Add USP Ascorbic Acid RS
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP43–NF38*	5476	24-Apr-2020	1-May-2020	*NA*	*NA*	In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid Method 3; Ascorbic Acid, Niacin or Niacinamide,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis: Add ascorbic acid ($C_6H_8O_6$), AND In *Molybdenum, Method 2/Instrumental conditions*: Change (See *Atomic Absorption Spectroscopy <852>*.) to: (See *Ultraviolet-Visible Spectroscopy <857>*.)
EPINEPHRINE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	1645	24-Apr-2020	1-May-2020	*NA*	*NA*	In the third calculation in the *Analysis*: Change C_U = concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Epinephrine in the *Sample solution* (mg/mL) to: C_U = concentration of Epinephrine in the *Sample solution* (µg/mL)
HEXYLENE GLYCOL	IMPURITIES/*Organic Impurities*	*USP43–NF38*	5814	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Any other individual impurity/Relative Response Factor* in *Table 2*: Change – to: 1.0
LOPERAMIDE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	2658	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability/Suitability requirements/Peak-to-valley ratio*: Change NLT 1.5 for loperamide related compounds G

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and H; NLT 1.5 for loperamide related compounds E and A, *System suitability solution* to: NLT 1.5 for loperamide *cis*-*N*-oxide and an hydroloperamide; NLT 1.5 for loperamide piperidinolamide and loperamide biphenyl analog, *System suitability solution*
0.02 M EDETATE DISODIUM VS	REAGENTS AND REFERENCE TABLES/*Solutions*	*USP43–NF38*	6240	24-Apr-2020	1-May-2020	*NA*	*NA*	Change 0.7444 g to: 7.444 g
POLYVINYL ALCOHOL	IDENTIFICATION/*A.*	*USP43–NF38*	3593	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Infrared Absorption* <197K> to: *Spectroscopic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Identification Tests <197>, *Infrared Spectroscopy*: 197K
RALTEGRAVIR TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
SACCHARIN SODIUM	SPECIFIC TESTS/*Readily Carbonizable Substances Test <271>*	*USP43–NF38*	3965	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Matching fluid A*: Change ferric chloride TS, to: ferric chloride CS,
BUDESONIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	604	24-Apr-2020	1-May-2020	*NA*	*NA*	In footnote k in *Table 2*: Change 16?,17-[Butylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,20-dione-21-acetate. to: 16?,17-[Butylidenebis(oxy)]-11?-hydroxypregna-1,4-diene-3,20-dione-21-yl acetate.
OIL-SOLUBLE VITAMINS TABLETS	ADDITIONAL REQUIREMENTS/*Labeling*	*USP43–NF38*	5356	24-Apr-2020	1-May-2020	*NA*	*NA*	In footnote 1: Change -alpha-tocopheryl to: *all-rac*-alpha-tocopheryl AND Change USP Vitamin E unit to: USP Vitamin E Unit AND Change 2*R*-alphatocopherol to: 2*R*-alpha-tocopherol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DEXAMETHASONE ACETATE	*Chromatographic purity*	*USP43–NF38*	1290	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Format buffer* to: *Formate buffer*
CAPRYLIC ACID	ASSAY/*Procedure*/*Chromatographic system*	*USP43–NF38*	5664	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Column*: Change 30-cm to: 30-m
LEUCOVORIN CALCIUM FOR INJECTION	ASSAY/*Procedure*/*Chromatographic system*	*USP43–NF38*	2569	24-Apr-2020	1-May-2020	*NA*	*NA*	Delete *Run time*: 2 times the retention time of the leucovorin peak
SUCROSE PALMITATE	IMPURITIES/*Inorganic Impurities*	*USP43–NF38*	6078	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Fats and Fixed Oils, Acid Value <401>*: Change NMT 6.0%, to: NMT 6.0,
NIACIN	IDENTIFICATION/*B.*	*USP43–NF38*	3138	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption* <197U> to: *Spectroscopic Identification Tests* <197>, *Ultraviolet-*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Visible Spectroscopy: 197U
NUCLEIC ACID-BASED TECHNIQUES -- GENERAL	APPENDICES	*USP43–NF38*	7865	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Appendix 2*: Delete the Row for dNTP dinucleotide triphosphate
ANTITHROMBIN III HUMAN	ADDITIONAL REQUIREMENTS	*USP42–NF37*	350	27-Mar-2020	1-Apr-2020	*NA*	*NA*	In *Labeling*: Change USP Antithrombin III Units. to: Antithrombin III IU.
ITRACONAZOLE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 1*	*Revision Bulletin (Official August 01, 2019)*	Online	27-Mar-2020	1-Apr-2020	*NA*	*NA*	In *System suitability/Suitability requirements/Relative standard deviation*: Change NMT 2.0% for 5 replicate injections to: NMT 2.0% for 5

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								replicates
ANTITHROMBIN III HUMAN	SPECIFIC TESTS	*USP42–NF37*	350	27-Mar-2020	1-Apr-2020	*NA*	*NA*	In *Pyrogen Test <151>*: Change USP Antithrombin III Units to: Antithrombin III IU
LITHIUM CARBONATE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*/*Test 1*	*USP42–NF37*	2598	28-Feb-2020	1-Mar-2020	*NA*	*NA*	In *Analysis*: Change *V* = volume of *Medium*, 900 mL to: *V* = volume of *Medium*, 800 mL
DICLOXACILLIN SODIUM CAPSULES	PERFORMANCE TESTS	*USP42–NF37*	1330	28-Feb-2020	1-Mar-2020	*NA*	*NA*	In *Dissolution <711>*: Change *Sample solution*: Sample per the chapter. Dilute with *Medium* to a concentration that is similar to the *Standard solution*. *Tolerances*: NLT 75% (*Q*) of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the labeled amount of dicloxacillin ($C_{19}H_{17}Cl_2N_3O_5S$) is dissolved. to: *Sample solution*: Sample per the chapter. Pass a portion of the solution under test through a suitable filter. Dilute with *Medium* to a concentration that is similar to the *Standard solution*. *Instrumental conditions* Mode: UV-Vis *Tolerances*: NLT 75% (*Q*) of the labeled amount of dicloxacillin ($C_{19}H_{17}Cl_2N_3O_5S$) is dissolved. In *Test*
CALCIUM	PERFORMANC	*Revision*	Online	28-Feb-2020	1-Mar-2020	*NA*	*NA*	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ACETATE CAPSULES	E TESTS/ *Dissolution <711>*	*Bulletin (Official January 01, 2020)*						*1/Analysis*: Change dissolved at time point (*i*): $Result_i = (r_U/r_S) \times C_S \times V \times D \times (1/L) \times 100$ to: dissolved: $Result = (r_U/r_S) \times C_S \times V \times D \times (1/L) \times 100$ AND In *Test 3/Analytical procedure 1/Analysis*: Change *V* = volume of *Medium*, 900 mL to: *V* = volume of *Medium 1*, 900 mL AND In *Test 3/Analytical procedure 2/Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								V_M = volume of *Medium*, 900 mL to: V_M = volume of *Medium 1*, 900 mL AND In *Test 3*/*Analytical procedure 3*/*Blank*: Change *Medium* to: *Medium 2* AND In *Test 3*/*Analytical procedure 3*/*Analysis*: Change V_M = volume of *Medium*, 900 mL to: V_M = volume of *Medium 2*, 900 mL
FLUNIXIN MEGLUMINE	IM PUR	*USP42–NF37*	1890	28-Feb-2020	1-Mar-2020	*NA*	*NA*	In *Sensitivity solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION	ITIES/*Organic Impurities*							Change in *Diluent* from the *Standard solution* to: in *Diluent*
POLYETHYLENE GLYCOL	CHEMICAL INFORMATION	*USP42–NF37*	5882	31-Jan-2020	1-Feb-2020	*NA*	*NA*	See https://www.usp nf.com/sites/default/files/usp_pdf/EN/january-2020-errata-with-image.pdf for correction
ALFADEX	CHEMICAL INFORMATION	*USP42–NF37*	5561	31-Jan-2020	1-Feb-2020	*NA*	*NA*	Change 972.84 to: 972.85
MEROPENEM FOR INJECTION	ASSAY/ *Procedure*	*Second Supplement to USP42–NF37*	9216	31-Jan-2020	1-Feb-2020	*NA*	*NA*	In *Mobile phase*: Change *Solution A* to: *Buffer*
ULTRAVIOLET-VISIBLE SPECTROSCOPY	QUALIFICATION OF UV-VIS SPECTROMETERS	*Second Supplement to USP42–NF37*	9570	27-Dec-2019	1-Jan-2020	*NA*	*NA*	In all instances in *Table 4*: Change < to: ? AND In *Control of*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Photometric Response/Acidic Nicotinic Acid Solutions in 0.1 N Hydrochloric Acid/paragraph 1: Change Using nicotinic acid solutions, the absorbance accuracy must be ± 0.01 $A_?$. to: Using nicotinic acid solutions, the absorbance accuracy must be ± 0.010 $A_?$ (for values below 1.00 $A_?$).
CYPROHEPTADINE HYDROCHLORIDE ORAL SOLUTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	1195	27-Dec-2019	1-Jan-2020	*NA*	*NA*	In *Standard solution*: Change in *Solution B* to: in *Diluent*
INSULIN ASSAYS	ASSAY/*Rabbit Blood Sugar Method—Quantitative*	*Revision Bulletin (Official May 01, 2019)*	Online	27-Dec-2019	1-Jan-2020	*NA*	*NA*	In *Standard stock solution*: Change of USP Insulin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS of the appropriate species to: of the USP Insulin Reference Standard of the appropriate species AND In *Sample stock solution*: Change of USP Insulin RS of the appropriate species. to: of the USP Insulin Reference Standard of the appropriate species.
CUPRIC CHLORIDE	REAGENTS AND REFERENCE TABLES/*Reagent Specifications*	*USP42–NF37*	6092	27-Dec-2019	1-Jan-2020	*NA*	*NA*	Change [7447-39-4]. to: [10125-13-0].

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
2,5-DIHYDROXYBENZOIC ACID	REAGENTS AND REFERENCE TABLES/*Reagent Specifications*	*USP42–NF37*	6097	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change [303-07-1]. to: [490-79-9].
ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—SMALL ANGLE X-RAY SCATTERING AND SMALL ANGLE NEUTRON SCATTERING	6. EXPERIMENTAL CONSIDERATIONS	*Second Supplement to USP42–NF37*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *6.2 Resolution*/*6.2.1 Size resolution*: Change $q_{min} < ?/d_{max}$ $?/d_{max}$ to: $q_{min} < ?/d_{max}$
SIMVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	4009	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Standard solution*: Change USP Simvastatin RS in *Medium* to: USP Simvastatin RS in *Medium*. Transfer a portion of the solution to a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								centrifuge tube containing about 10 mg of *Prewashed manganese dioxide* per milliliter of transferred solution under test, and mix. Allow the mixture to stand for 30 min with occasional shaking, centrifuge, and use a portion of the clear supernatant.
VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPEIAL ARTICLES	VALIDATION OF NEUTRALIZATION METHODS—RECOVERY COMPARISONS	*Second Supplement to USP42–NF37*	9616	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In paragraph 1 in *Recovery on Agar Medium*: Change If it is necessary to solubilize the test stample, to: If it is necessary to solubilize the test sample,
MEFENAMIC	PERFORMANC	*USP42–NF37*	2711	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ACID CAPSULES	E TESTS/ *Dissolution* <*711*>							*Solution A*, *Mobile phase*, *Standard solution*, *Sample solution*, *Chromatographic system*, and *System suitability*: Proceed as directed in the *Assay*, making any necessary volumetric adjustments. to: *Solution A*, *Mobile phase*, *Standard solution*, *Chromatographic system*, and *System suitability*: Proceed as directed in the *Assay*, making any necessary volumetric adjustments.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
0.1 N POTASSIUM HYDROXIDE VS	REAGENTS AND REFERENCE TABLES/*Solutions*	*USP42–NF37*	6185	22-Nov-2019	1-Dec-2019	*NA*	*NA*	*Sample solution*: Take a portion of the solution under test, and dilute if necessary. Change *Standardization*: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N potassium hydroxide VS. Titrate with 0.1 N hydrochloric acid VS until a permanent pale-pink color is produced. to: *Standardization*: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N hydrochloric acid VS. Titrate with the potassium hydroxide solution until a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								permanent pale-pink color is produced.
ROPINIROLE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official July 01, 2019)*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Test 2* and *Test 3* in *Analysis*: Change $Result_1 = C_1 \times (1/L) \times (M_{r1}/M_{r2}) \times 100$ to: $Result_1 = C_1 \times V \times (1/L) \times (M_{r1}/M_{r2}) \times 100$
ZIPRASIDONE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 3/Tier 2*	*Revision Bulletin (Official October 01, 2019)*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Buffer*: Change 6.8 g/L g to: 6.8 g/L AND In *Standard stock solution 2*: Change *Standard stock solution* to: *Standard stock solution 1*
ANALYTICAL METHODOLOGIES BASED ON	1. OVERVIEW: GENERAL CHAPTERS	*Second Supplement to USP42–NF37*	9634	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In Row 6 of Column 4 in *Table 1*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SCATTERING PHENOMENA—GENERAL	BASED ON SCATTERING PHENOMENA							Change Also properties of condensated phrases to: Also properties of condensated phases
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS	IM PURITIES/*Organic Impurities*	*Second Supplement to USP42–NF37*	9101	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Table 4, Footnote h*: Change 0.47, to: 0.45,

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »